|Place your mouse over each cart item to see full description.
MediSave.ca is Moving!
MediSave is merging with our flagship website CanadaPharmacyOnline.com.
CPO provides the same prices for products from the same suppliers, the same outstanding customer service, but cheaper shipping for customers.
If you are an existing customer, your account will be transferred to CPO.
You can do the transfer your self by clicking Transfer to CPO
If you have questions, please call Medisave customer service at 1.877.888.3784. A customer service repesentitive will answer your questions and do the transfer for you.
Not an existing customer? It is a good oppertunity to open your account with us by clicking CanadaPharmacyOnline.com
Chemical Name: Cabergoline
DOSTINEX(Cabergoline) Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 Dopamine receptors. Dopamine agonists such as DOSTINEX(Cabergoline) in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia and eclampsia, unless the potential benefit is judged to outweigh the possible risk. The prolactin-lowering action of cabergoline suggests that it will interfere with lactation. Due to this interference with lactation, DOSTINEX(Cabergoline) should not be given to women postpartum who are breastfeeding or who are planning to breastfeed.
DOSTINEX (Cabergoline) Tablets are white, scored, capsule-shaped tablets containing 0.5 mg cabergoline. Each tablet of DOSTINEX (Cabergoline) is scored on one side and has the letter P and the letter U on either side of the breakline. The other side of the DOSTINEX(Cabergoline) tablet is engraved with the number 700. DOSTINEX (Cabergoline) is avilable in bottles of 8 tablets.
Dostinex Side Effects:
DOSTINEX(Cabergoline) side effects include: nausea, constipation, abdominal pain, dyspepsia and vomiting, headache, and dizziness. Initial doses higher than DOSTINEX(Cabergoline) 1.0 mg may produce DOSTINEX(Cabergoline) side effects like orthostatic hypotension. Care should be exercised when administering DOSTINEX(Cabergoline) with other medications known to produce DOSTINEX(Cabergoline) side effects like lower blood pressure.
The recommended dosage of DOSTINEX(Cabergoline) Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level.
Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with-higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered.
The generic alternative is not manufactured by the company that makes the brand product.
All prices are in US dollars.ollars.
The content on this page has been supplied to MediSave.ca by an independent third party contracted to provide information for our website. MediSave.ca relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.
Back to Main Drug Information Page